Taipei, Taiwan, October 13, 2020 — Steminent Biotherapeutics Inc. (President & CEO; Dr. Ling-Mei Wang) and SCM Lifescience Co., Ltd. (KOSDAQ: 298060, hereinafter SCM Lifescience, CEO: BG Rhee) today announced they have signed an exclusive license agreement for clinical development and commercialization of Steminent’s allogeneic cell therapy candidate; Stemchymal® for the treatment of Polyglutamine Spinocerebellar Ataxia (PolyQ SCAs) in South Korea. [Read more…]
ReeLabs Approved to Conduct First and Only Stem Cell Trial Against COVID-19 in India
ReeLabs received permission from the Central Licensing Authority to conduct the first and only trial in India using MSCs from placenta and umbilical cord tissue against COVID-19.
There are numerous publications that have documented the role of stem cell against COVID-19. Currently there are 23 stem cell trials in progress in US, UK, Japan, Germany, China, Spain, France and various other developed countries and hitherto published literature is extremely encouraging.
India is now all set to join this elite list. [Read more…]
Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy
Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. [Read more…]
TreeFrog Therapeutics and Invetech Expand Partnership to Transition High-throughput Stem Cell Encapsulation Technology to GMP System for Commercial-scale Cell Therapy Manufacturing
-
TreeFrog Therapeutics and Invetech started their collaboration in 2019 to industrialize TreeFrog’s stem cell encapsulation technology to enable the mass production of hPSC-derived cell therapies in industrial bioreactors, with best-in-class cell quality and low production costs.
-
Invetech delivered a beta encapsulation system with a throughput of 1,000 stem cell capsules per second to TreeFrog Therapeutics in the second quarter of 2020.
-
The strategic partnership aims to develop a GMP-compliant encapsulation device by the end of 2022 to support TreeFrog Therapeutics’ in-house and partnered cell therapy programs.
Stem Cell Transplants: What To Know About This Life-Saving Procedure
Stem cell transplants are a medical procedure in which which stem cells are transplanted into an injured or diseased recipient. This procedure can either involve stem cells derived from one’s self or stem cells derived from a healthy donor.
In this article:
- « Previous Page
- 1
- …
- 183
- 184
- 185
- 186
- 187
- …
- 338
- Next Page »